Onkologie. 2016:10(1):11-14 | DOI: 10.36290/xon.2016.004

Diagnostic and therapeutic guidelines for stage III non-small-cell lung cancer

Gabriela Krákorová
Klinika pneumologie a ftizeologie FN Plzeň

Stage III non-small-cell lung cancer (NSCLC) has a low 5-year survival rate (less than 30%). In order to have a real chance of improving

patient survival, both staging and treatment must be of appropriate quality. During staging, it is important to precisely

determine regional lymph node involvement and rule out generalization. PET/CT (positron emission tomography/computed

tomography) of the torso is recommended to be used for regional lymph node staging. Positive findings that alter the stage

are to be confirmed bioptically. Treatment is always indicated strictly individually, ideally within multidisciplinary teams; it is

multimodal, using multiple therapeutic methods (chemotherapy, radiotherapy, surgery). For stage III patients, immunotherapy

is a promising approach for the future.

Keywords: stage III, NSCLC, multimodal, FNAB, EBUS, EUS, immunotherapy

Published: March 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krákorová G. Diagnostic and therapeutic guidelines for stage III non-small-cell lung cancer. Onkologie. 2016;10(1):11-14. doi: 10.36290/xon.2016.004.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. NCCN Guidelines for Non-Small Cell Lung Cancer v. 1 2015, dostupné z: www.nccn.org, [cit. 2015-11-27].
    2. Eberhardt WEE, De Ruysscher D, Weder W, et al. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol. 2015; 26: 8: 1573-1588. Go to original source... Go to PubMed...
    3. Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5 Suppl): 211-250. Go to original source... Go to PubMed...
    4. Tahara RW, Lackner RP, Graver LM, et al. Is there a role for routine mediastinoscopy in patients with peripheral T1 lung cancers? Am J Surg 2000; 180: 488-491. Go to original source... Go to PubMed...
    5. Wallace MB, Ravenel J, Block MI, et al. Endoscopic ultrasound in lung cancer patients with a normal mediastinum on computed tomography. Ann Thorac Surg 2004; 77: 1763-1768. Go to original source...
    6. Herth FJ, Eberhardt R, Krasnik M, Ernst A. Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically and positron emission tomography-normal mediastinum in patients with lung cancer. Chest 2008; 133: 4: 887-891. Go to original source...
    7. Annema JT, van Meerbeeck JP, Rintoul RC, et al. Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial. Jama 2010; 2245-2252. Go to original source... Go to PubMed...
    8. Robinson LA, Ruckdeschel JC, Wagner H Jr, Stevens CW. American College of Chest Physicians. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132(3): (Suppl): 243-265. Go to original source...
    9. Pneumologie.cz [internetová stránka]. Česká pneumologická a ftizeologická společnost ČLS JEP, Česká Republika; Guidelines, NSCLC, Odborná část, Klinický standard komplexní péče o pacienty s bronchogenním nemalobuněčným karcinomem plic, verze 1.0, [aktualizováno duben 2012; cit. 2015-10-30]. Dostupné z: http://www.pneumologie.cz/guidelines/.
    10. Pignon JP, Tribodet H, Scagliotti GV. Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26(21): 3552-3559. Go to original source... Go to PubMed...
    11. Choy H, Gerber DE, Bradley JD. Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies. Lung Cancer 2015; 87(3): 232-240. Go to original source... Go to PubMed...
    12. Vokes EE, Senan S, Treat JA, et al. PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology. Clin Lung Cancer 2009 May; 10(3): 193-198. Go to original source...
    13. Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 2013; 31(23): 2895-2902. Go to original source...
    14. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550. Go to original source...
    15. Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008; 26(35): 5755-5760. Go to original source... Go to PubMed...
    16. Carter DL, Garfield D, Hathorn J, et al. A randomized phase III trial of combined paclitaxel, carboplatin, and radiation therapy followed by weekly paclitaxel or observation for patients with locally advanced inoperable non-small-cell lung cancer. Clin Lung Cancer 2012; 13: 205-213. Go to original source... Go to PubMed...
    17. Kelly K, Chansky K, Gaspar LE. Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non-Small-Cell Lung Cancer: SWOG S0023. J Clin Oncol 2008; 26(15): 2450-2456. Go to original source... Go to PubMed...
    18. Goss GD, O'Callaghan GH, Lorimer I, et al. Gefitinib Versus Placebo in Completely Resected Non-Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study. J Clin Oncol 2013; 31(27): 3320-3326. Go to original source... Go to PubMed...
    19. Kelly K, Altorki NK, Eberhardt WEE, et al. Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): A randomized, double-blind, phase III trial. J Clin Oncol, doi: 10.1200/JCO.2015.61.8918.
    20. Vansteenkiste J, Cho BC, De Pas T, et al. MAGRIT, a double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of the recMAGE-A3 + AS15 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small cell lung cancer (NSCLC). ESMO 2014 congress, Madrid, abstrakt 11730. Go to original source...
    21. Butts CH, Socinski MA, Mitchell PL, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. The Lancet 2014; 15(1): 59-68. Go to original source... Go to PubMed...
    22. Vizualizace punktované uzliny pomocí EBUS. Dostupné z <http://www.cpd.utoronto.ca/ebus/> [PŘÍSTUP: 12-02-2015]

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.